• Weekly Cumulative Estimated Number of RSV Vaccinations Administered in Retail Pharmacies and Physicians’ Medical Offices, Adults 50–74 Years and 75 Years and Older, United States

• In June 2023, the Advisory Committee on Immunization Practices (ACIP) voted to recommend that adults aged ≥60 years may receive a single dose of an RSV vaccine, using shared clinical decision-making. In June 2024, the ACIP voted to recommend a single dose of RSV vaccine for all adults 75 years and older and adults 60–74 years who are at increased risk for severe RSV disease.† On June 26, 2024, CDC adopted these recommendations. In April 2025, ACIP recommended that adults 50–59 years who are at increased risk for severe RSV disease were added to the previous recommendation. This recommendation was adopted by the HHS Secretary on June 25, 2025. The data below capture the number of RSV doses administered to adults 50 years and older.†

• The projected pharmacy estimates are based on IQVIA‡,§ Longitudinal Prescription Claims (LRx) (https://www.iqvia.com/insights/the-iqvia-institute/available-iqvia-data) and vaccinations administered in retail pharmacies (including chain, mass merchandise, food stores, and independent pharmacies). ± The projected physicians’ medical offices estimates are based on IQVIA’s Medical Claims (Dx) (https://www.iqvia.com/insights/the-iqvia-institute/available-iqvia-data).^

• Vaccinations administered in workplaces, community locations, long-term care settings, and other medical settings such as public health clinics are not represented in these data.

Tags: nis-acm, iis, iqvia, vsd, rsv vaccination

Last updated: 2025-11-20 22:10:41+00:00